Larimar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for patients suffering from rare diseases using its cell penetrating peptide technology platform. Co.'s lead product candidate, CTI-1601, is a biologic fusion protein that is administered subcutaneously, consists of a cell penetrating peptide (CPP) genetically fused to human frataxin (FXN), and includes a mitochondrial targeting sequence. Using its proprietary peptide delivery technology, CTI-1601 carries the molecule from the intravascular space across the cell membrane and into the mitochondria where the CPP and the mitochondrial targeting sequence are cleaved off to yield mature FXN. We show 14 historical shares outstanding datapoints in our LRMR shares outstanding history coverage, used to compute LRMR market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing LRMR market cap history over the course of time is important for investors
interested in comparing LRMR's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of LRMR versus a peer is one thing; comparing
LRMR market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like LRMR can fluctuate over the course of history.
With this page we aim to empower investors researching LRMR by allowing them to research the LRMR market cap history. |
Free LRMR Email Alerts:
Video: The Importance of Market Cap
